Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial

Leukotrienes are pro-inflammatory mediators which may contribute to tissue, sputum, and blood eosinophilia seen in allergic and inflammatory diseases, including asthma. Montelukast is a cysteinyl leukotriene1 (CysLT1) receptor antagonist which improves asthma control; the aim of this study was to investigate its effect on induced sputum eosinophils. Montelukast 10 mg (n=19) or placebo (n=21) were administered orally once in the evening for 4 weeks to 40 chronic adult asthmatic patients, aged 19-64 yrs, in a double-blind, randomized, parallel group study. Patients were included if, at prestudy, they had >5% sputum eosinophils, symptomatic asthma with a forced expiratory volume in one second > or =65% of the predicted value and were being treated only with "as needed" inhaled beta2-agonists. In addition to sputum eosinophils, blood eosinophils and clinical endpoints were also assessed. Four weeks of montelukast treatment decreased sputum eosinophils from 7.5% to 3.9% (3.6% decrease, 95% confidence interval (CI) -16.6-0.4). In contrast, placebo treatment was associated with an increase in sputum eosinophils from 14.5% to 17.9% (3.4% increase, 95% CI -3.5-9.8). The least squares mean difference between groups (-11.3%, 95% CI -21.1-(-1.4)) was significant (p=0.026). Compared with placebo, montelukast significantly reduced blood eosinophils (p=0.009), asthma symptoms (p=0.001) and beta2-agonist use (p<0.001) while significantly increasing morning peak expiratory flow (p=0.001). Montelukast was generally well tolerated in this study, with a safety profile similar to the placebo. These results demonstrate that montelukast decreases airway eosinophilic inflammation in addition to improving clinical parameters. Its efficacy in the treatment of chronic asthma may be due, in part, to the effect on airway inflammation.

This article has been cited by other articles:

				L. Bjermer Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefits Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 149 - 161. [Abstract] [PDF]

				A. J. Robinson, D. Kashanin, F. O'Dowd, V. Williams, and G. M. Walsh Montelukast inhibition of resting and GM-CSF-stimulated eosinophil adhesion to VCAM-1 under flow conditions appears independent of cysLT1R antagonism J. Leukoc. Biol., June 1, 2008; 83(6): 1522 - 1529. [Abstract] [Full Text] [PDF]

				S Joos, A Miksch, J Szecsenyi, B Wieseler, U Grouven, T Kaiser, and A Schneider Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Thorax, May 1, 2008; 63(5): 453 - 462. [Abstract] [Full Text] [PDF]

				C. Thompson, A. Cloutier, Y. Bosse, M. Thivierge, C. L. Gouill, P. Larivee, P. P. McDonald, J. Stankova, and M. Rola-Pleszczynski CysLT1 Receptor Engagement Induces Activator Protein-1- and NF-{kappa}B-Dependent IL-8 Expression Am. J. Respir. Cell Mol. Biol., December 1, 2006; 35(6): 697 - 704. [Abstract] [Full Text] [PDF]

				D. C. Kim, F. I. Hsu, N. A. Barrett, D. S. Friend, R. Grenningloh, I-C. Ho, A. Al-Garawi, J. M. Lora, B. K. Lam, K. F. Austen, et al. Cysteinyl Leukotrienes Regulate Th2 Cell-Dependent Pulmonary Inflammation J. Immunol., April 1, 2006; 176(7): 4440 - 4448. [Abstract] [Full Text] [PDF]

				M. E. Strek Difficult asthma. Proceedings of the ATS, January 1, 2006; 3(1): 116 - 123. [Abstract] [Full Text] [PDF]

				A. Coreno, M. Skowronski, E. West, A. El-Ekiaby, and E.R. McFadden Jr Bronchoprotective Effects of Single Doses of Salmeterol Combined With Montelukast in Thermally Induced Bronchospasm Chest, May 1, 2005; 127(5): 1572 - 1578. [Abstract] [Full Text] [PDF]

				W. Busse and M. Kraft Cysteinyl Leukotrienes in Allergic Inflammation: Strategic Target for Therapy Chest, April 1, 2005; 127(4): 1312 - 1326. [Abstract] [Full Text] [PDF]

				L Jayaram, E Pizzichini, C Lemiere, S F P Man, A Cartier, F E Hargreave, and M M M Pizzichini Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast Thorax, February 1, 2005; 60(2): 100 - 105. [Abstract] [Full Text] [PDF]

				L. Jayaram, M. Duong, M. M. M. Pizzichini, E. Pizzichini, D. Kamada, A. Efthimiadis, and F. E. Hargreave Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma Eur. Respir. J., January 1, 2005; 25(1): 41 - 46. [Abstract] [Full Text] [PDF]

				E. S. Mendes, M. A. Campos, A. Hurtado, and A. Wanner Effect of Montelukast and Fluticasone Propionate on Airway Mucosal Blood Flow in Asthma Am. J. Respir. Crit. Care Med., May 15, 2004; 169(10): 1131 - 1134. [Abstract] [Full Text] [PDF]

				K. Parameswaran, R. Watson, G. M. Gauvreau, R. Sehmi, and P. M. O'Byrne The Effect of Pranlukast on Allergen-induced Bone Marrow Eosinophilopoiesis in Subjects with Asthma Am. J. Respir. Crit. Care Med., April 15, 2004; 169(8): 915 - 920. [Abstract] [Full Text] [PDF]

				L. Bjermer, H. Bisgaard, J. Bousquet, L. M Fabbri, A. P Greening, T. Haahtela, S. T Holgate, C. Picado, J. Menten, S B. Dass, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial BMJ, October 18, 2003; 327(7420): 891. [Abstract] [Full Text] [PDF]

				A. Sandrini, I. M. Ferreira, C. Gutierrez, J. R. Jardim, N. Zamel, and K. R. Chapman Effect of Montelukast on Exhaled Nitric Oxide and Nonvolatile Markers of Inflammation in Mild Asthma Chest, October 1, 2003; 124(4): 1334 - 1340. [Abstract] [Full Text] [PDF]

				R H Green, C E Brightling, I D Pavord, and A J Wardlaw Management of asthma in adults: current therapy and future directions Postgrad. Med. J., May 1, 2003; 79(931): 259 - 267. [Abstract] [Full Text] [PDF]

				K. Chibana, Y. Ishii, T. Asakura, and T. Fukuda Up-Regulation of Cysteinyl Leukotriene 1 Receptor by IL-13 Enables Human Lung Fibroblasts to Respond to Leukotriene C4 and Produce Eotaxin J. Immunol., April 15, 2003; 170(8): 4290 - 4295. [Abstract] [Full Text] [PDF]

				M J Vaquerizo, P Casan, J Castillo, M Perpina, J Sanchis, V Sobradillo, A Valencia, H Verea, J L Viejo, C Villasante, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma Thorax, March 1, 2003; 58(3): 204 - 210. [Abstract] [Full Text] [PDF]

				D B Price, D Hernandez, P Magyar, J Fiterman, K M Beeh, I G James, S Konstantopoulos, R Rojas, J A van Noord, M Pons, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma Thorax, March 1, 2003; 58(3): 211 - 216. [Abstract] [Full Text] [PDF]

				S. O'Sullivan, M. Akveld, C. M. Burke, and L. W. Poulter Effect of the Addition of Montelukast to Inhaled Fluticasone Propionate on Airway Inflammation Am. J. Respir. Crit. Care Med., March 1, 2003; 167(5): 745 - 750. [Abstract] [Full Text] [PDF]

				W. M. Abraham Of Mice and Men Am. J. Respir. Cell Mol. Biol., January 1, 2003; 28(1): 1 - 4. [Full Text] [PDF]

				S.-Y. Eum, K. Maghni, Q. Hamid, H. Campbell, D. H. Eidelman, and J. G. Martin Involvement of the Cysteinyl-Leukotrienes in Allergen-Induced Airway Eosinophilia and Hyperresponsiveness in the Mouse Am. J. Respir. Cell Mol. Biol., January 1, 2003; 28(1): 25 - 32. [Abstract] [Full Text] [PDF]

				F. Kanniess, K. Richter, S. Janicki, M.B. Schleiss, R.A. Jorres, and H. Magnussen Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Eur. Respir. J., November 1, 2002; 20(5): 1080 - 1087. [Abstract] [Full Text] [PDF]

				R. Leigh, D. Vethanayagam, M. Yoshida, R. M. Watson, T. Rerecich, M. D. Inman, and P. M. O'Byrne Effects of Montelukast and Budesonide on Airway Responses and Airway Inflammation in Asthma Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1212 - 1217. [Abstract] [Full Text] [PDF]

				F. Kanniess, K. Richter, S. Bohme, R.A. Jorres, and H. Magnussen Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma Eur. Respir. J., October 1, 2002; 20(4): 853 - 858. [Abstract] [Full Text] [PDF]

				L. Ghiro, S. Zanconato, O. Rampon, V. Piovan, M.F. Pasquale, and E. Baraldi Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children Eur. Respir. J., September 1, 2002; 20(3): 630 - 634. [Abstract] [Full Text] [PDF]

				Leader of the Working Group:, I.D. Pavord, Members of the Working Group:, P.J. Sterk, F.E. Hargreave, J.C. Kips, M.D. Inman, R. Louis, M.M.M. Pizzichini, E.H. Bel, et al. Clinical applications of assessment of airway inflammation using induced sputum Eur. Respir. J., July 1, 2002; 20(37_suppl): 40S - 43s. [Full Text] [PDF]

				S. Nag, B. Lamkhioued, and P. M. Renzi Interleukin-2-induced Increased Airway Responsiveness and Lung Th2 Cytokine Expression Occur after Antigen Challenge through the Leukotriene Pathway Am. J. Respir. Crit. Care Med., June 1, 2002; 165(11): 1540 - 1545. [Abstract] [Full Text] [PDF]

				A. Efthimiadis, L. Jayaram, S. Weston, S. Carruthers, and F.E. Hargreave Induced sputum: time from expectoration to processing Eur. Respir. J., April 1, 2002; 19(4): 706 - 708. [Abstract] [Full Text] [PDF]

				K. Minoguchi, Y. Kohno, H. Minoguchi, N. Kihara, Y. Sano, H. Yasuhara, and M. Adachi Reduction of Eosinophilic Inflammation in the Airways of Patients With Asthma Using Montelukast Chest, March 1, 2002; 121(3): 732 - 738. [Abstract] [Full Text] [PDF]

				W. R. HENDERSON JR., L.-O. TANG, S.-J. CHU, S.-M. TSAO, G. K. S. CHIANG, F. JONES, M. JONAS, C. PAE, H. WANG, and E. Y. CHI A Role for Cysteinyl Leukotrienes in Airway Remodeling in a Mouse Asthma Model Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 108 - 116. [Abstract] [Full Text] [PDF]

				J. V. FAHY, H. A. BOUSHEY, S. C. LAZARUS, E. A. MAUGER, R. M. CHERNIACK, V. M. CHINCHILLI, T. J. CRAIG, J. M. DRAZEN, J. G. FORD, J. E. FISH, et al. Safety and Reproducibility of Sputum Induction in Asthmatic Subjects in a Multicenter Study Am. J. Respir. Crit. Care Med., May 1, 2001; 163(6): 1470 - 1475. [Abstract] [Full Text]

				H. Gong Jr., W. S. Linn, S. L. Terrell, K. R. Anderson, and K. W. Clark Anti-inflammatory and Lung Function Effects of Montelukast in Asthmatic Volunteers Exposed to Sulfur Dioxide Chest, February 1, 2001; 119(2): 402 - 408. [Abstract] [Full Text] [PDF]

				H. Bisgaard Leukotriene Modifiers in Pediatric Asthma Management Pediatrics, February 1, 2001; 107(2): 381 - 390. [Abstract] [Full Text]

				D. J. FIGUEROA, R. M. BREYER, S. K. DEFOE, S. KARGMAN, B. L. DAUGHERTY, K. WALDBURGER, Q. LIU, M. CLEMENTS, Z. ZENG, G. P. O'NEILL, et al. Expression of the Cysteinyl Leukotriene 1 Receptor in Normal Human Lung and Peripheral Blood Leukocytes Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 226 - 233. [Abstract] [Full Text]

				G. Ménard and E. Y. Bissonnette Priming of Alveolar Macrophages by Leukotriene D4 . Potentiation of Inflammation Am. J. Respir. Cell Mol. Biol., October 1, 2000; 23(4): 572 - 577. [Abstract] [Full Text]

				J. CHRISTIAN VIRCHOW Jr., A. PRASSE, I. NAYA, L. SUMMERTON, A. HARRIS, and The Zafirlukast Study Group Zafirlukast Improves Asthma Control in Patients Receiving High-Dose Inhaled Corticosteroids Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 578 - 585. [Abstract] [Full Text] [PDF]

				H. BISGAARD and K. G. NIELSEN Bronchoprotection with a Leukotriene Receptor Antagonist in Asthmatic Preschool Children Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 187 - 190. [Abstract] [Full Text]

				E. LEE, T. ROBERTSON, J. SMITH, and S. KILFEATHER Leukotriene Receptor Antagonists and Synthesis Inhibitors Reverse Survival in Eosinophils of Asthmatic Individuals Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1881 - 1886. [Abstract] [Full Text]

				M. Hojo, M. Suzuki, K. Maghni, Q. Hamid, W. S. Powell, and J. G. Martin Role of Cysteinyl Leukotrienes in CD4+ T Cell-Driven Late Allergic Airway Responses J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 410 - 416. [Abstract] [Full Text]